Celecoxib and Diclofenac Plus Omeprazole are Similarly Effective in the Treatment of Arthritis in Patients at High GI Risk in the CONDOR Trial

The Open Rheumatology Journal
Herbert L KellnerMargaret N Essex

Abstract

Compare effectiveness of celecoxib versus diclofenac plus omeprazole in improving arthritis signs and symptoms in patients at high gastrointestinal (GI) risk who were enrolled in the CONDOR (Celecoxib vs Omeprazole and Diclofenac in Patients With Osteoarthritis and Rheumatoid Arthritis) trial. CONDOR was a 6-month, prospective, double-blind, triple-dummy, parallel-group, randomized, multicenter trial comparing celecoxib 200 mg twice daily versus diclofenac slow release (SR) 75 mg twice daily plus omeprazole 20 mg daily. Patients were Helicobacter pylori negative, had osteoarthritis (OA) or rheumatoid arthritis (RA), were aged ≥60 years, were with or without a history of gastroduodenal ulceration, or were ≥18 years with previous gastroduodenal ulceration. Patients' Global Assessment of Arthritis was determined at each study visit. A total of 4484 patients were randomized to treatment (2238 celecoxib, 2246 diclofenac SR) and included in the intention-to-treat analyses. Least squares mean (LSM) (standard error [SE]) for Patients' Global Assessment of Arthritis was 3.219 (0.017) and 3.221 (0.017) at baseline for celecoxib and diclofenac SR (p=0.90). Improvement in both groups was similar in months 2, 4, and 6; at month 1 the LSM (S...Continue Reading

References

Sep 10, 1992·The New England Journal of Medicine·M C AllisonR I Russell
Dec 2, 1999·JAMA : the Journal of the American Medical Association·L S SimonG S Geis
Mar 17, 2001·Scandinavian Journal of Rheumatology·F McKennaG S Geis
Dec 27, 2002·The New England Journal of Medicine·Francis K L ChanJoseph J Y Sung
Jan 16, 2003·Seminars in Arthritis and Rheumatism·Loren Laine
Dec 3, 2003·Annals of the Rheumatic Diseases·K M JordanUNKNOWN Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT
Oct 9, 2004·Annals of the Rheumatic Diseases·W ZhangUNKNOWN EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
Jan 13, 2005·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·David Y GrahamWaqar A Qureshi
Feb 11, 2005·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Jay L GoldsteinUNKNOWN Investigators
Jan 6, 2006·The Journal of Clinical Investigation·Tilo GrosserGarret A FitzGerald
Apr 25, 2008·Journal of Clinical Pharmacology·Jules I SchwartzJohn A Wagner
Oct 16, 2008·The American Journal of Gastroenterology·Francis K L ChanUNKNOWN First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and
May 19, 2009·Gastroenterology Clinics of North America·Angel Lanas, Federico Sopeña
Mar 11, 2010·Annals of the Rheumatic Diseases·Josef S SmolenUNKNOWN T2T Expert Committee

❮ Previous
Next ❯

Citations

Jan 19, 2016·Expert Review of Gastroenterology & Hepatology·Luigi MelcarneXavier Calvet
Jun 10, 2017·The Cochrane Database of Systematic Reviews·Mahir FidahicLivia Puljak

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.